Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 4Recruiting 3Completed 3Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Doxorubicin 4Cetuximab 4durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Platinum 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × fluzoparib × 1 year × Clear all
NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Suspended
80 enrolled
Breast

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡